Not gonna lie, have a couple of pre-existing conditions and have been intubated in grave condition and survived due to a severe asthma attack 20 years ago, went 8 minutes without drawing a breath, heart pretty much stopped and then that rookie er doc managed to get the tube in me just in time. I will be fighting my way to get it as soon as I can because I have a wife and three kids that need me. I don't want to suffocate to death again or ever get tubed again. [Reply]
Originally Posted by bringbackmarty:
Not gonna lie, have a couple of pre-existing conditions and have been intubated in grave condition and survived due to a severe asthma attack 20 years ago, went 8 minutes without drawing a breath, heart pretty much stopped and then that rookie er doc managed to get the tube in me just in time. I will be fighting my way to get it as soon as I can because I have a wife and three kids that need me. I don't want to suffocate to death again or ever get tubed again.
The 50% neutralizing geometric mean titers elicited by 30 μg of BNT162b2 in older and younger adults exceeded the geometric mean titer measured in a human convalescent serum panel, despite a lower neutralizing response in older adults than in younger adults
What that means: it generated a stronger immune response than seen in plasma of those previously infected with COVID
Supplemental analyses indicated that vaccine efficacy among subgroups defined by age, sex, race, ethnicity, obesity, and presence of a coexisting condition was generally consistent with that observed in the overall population
... The study was not designed to assess the efficacy of a single-dose regimen. Nevertheless, in the interval between the first and second doses, the observed vaccine efficacy against Covid-19 was 52%, and in the first 7 days after dose 2, it was 91%, reaching full efficacy against disease with onset at least 7 days after dose 2.
What that means: although not definitive, protective benefits are likely even after the first injection [Reply]
The 50% neutralizing geometric mean titers elicited by 30 μg of BNT162b2 in older and younger adults exceeded the geometric mean titer measured in a human convalescent serum panel, despite a lower neutralizing response in older adults than in younger adults
What that means: it generated a stronger immune response than seen in plasma of those previously infected with COVID
Supplemental analyses indicated that vaccine efficacy among subgroups defined by age, sex, race, ethnicity, obesity, and presence of a coexisting condition was generally consistent with that observed in the overall population
... The study was not designed to assess the efficacy of a single-dose regimen. Nevertheless, in the interval between the first and second doses, the observed vaccine efficacy against Covid-19 was 52%, and in the first 7 days after dose 2, it was 91%, reaching full efficacy against disease with onset at least 7 days after dose 2.
What that means: although not definitive, protective benefits are likely even after the first injection
Very impressive.
I'm hopeful Moderna has similar results to share with us next week. [Reply]
The 50% neutralizing geometric mean titers elicited by 30 μg of BNT162b2 in older and younger adults exceeded the geometric mean titer measured in a human convalescent serum panel, despite a lower neutralizing response in older adults than in younger adults
What that means: it generated a stronger immune response than seen in plasma of those previously infected with COVID
Supplemental analyses indicated that vaccine efficacy among subgroups defined by age, sex, race, ethnicity, obesity, and presence of a coexisting condition was generally consistent with that observed in the overall population
... The study was not designed to assess the efficacy of a single-dose regimen. Nevertheless, in the interval between the first and second doses, the observed vaccine efficacy against Covid-19 was 52%, and in the first 7 days after dose 2, it was 91%, reaching full efficacy against disease with onset at least 7 days after dose 2.
What that means: although not definitive, protective benefits are likely even after the first injection
So with that, wouldn’t it be smarter to vaccinate as many as you can with a single shot vs two? Could spread it out more. [Reply]
Originally Posted by O.city:
So with that, wouldn’t it be smarter to vaccinate as many as you can with a single shot vs two? Could spread it out more.
The study wasn't powered to analyze efficacy after the first shot. That data is suggestive, not definitive. It was powered to analyze efficacy after the second shot, and it offers a clear and demonstrable increase in efficacy from the first shot. I would stick with the two shot series. [Reply]